Retreatement with relmacabtagene for relapsed B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 4 trial looks at giving a second infusion of relmacabtagene autoleucel (a CAR-T cell therapy) to people whose B-cell lymphoma came back or did not respond after the first treatment. It may help by reducing lymphoma activity again, but you can only continue if you safely recovered from the first treatment and meet specific safety and lab requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have consented to join the study
- You have relapsed or refractory B-cell lymphoma (specific types listed by the study)
- You previously received relmacabtagene autoleucel and your doctor decided a second infusion is appropriate based on your history and scans
- Before the second infusion, you must have enough of the prepared product dose available and (in many cases) evidence of CD19 on tumor cells
- No serious ongoing side effects from the first treatment; prior chemotherapy side effects should have mostly gone back to near normal (except hair loss)
- No allergy to the study medicine ingredients; infections must be controlled (no uncontrolled serious fungal/bacterial/viral infections)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at giving a second dose of relma-cel (a type of CAR-T therapy) for B-cell lymphoma that came back or did not fully respond after the first treatment. It may help shrink tumors again, but it requires that side effects from the first treatment and pre-chemo are mostly gone and that you meet infection and blood-test safety checks.
This trial tests an experimental CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to find and attack cancer cells.
This study looks at people who have already received a CAR T-cell therapy called Relma-cel for blood cancers. It aims to understand how they are doing and may involve keeping track of their health over time.
This trial tests a new type of CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) for people with B-cell lymphomas that have come back or not responded to standard treatments. It aims to see if this new manufacturing method is safe and effective.
This trial tests a combination treatment: a stem cell transplant followed by CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. It is for those with high-risk features like large tumors or certain genetic changes.
This trial tests a combination of two treatments: a CAR-T cell therapy (relmacabtagene autoleucel) and an immunotherapy drug (sintilimab) for people with certain types of B-cell lymphoma that have come back or stopped responding to other treatments. The goal is to see if this combination can help control the cancer.
Hear when a new Relapsed or Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.